Efficacy and Safety of Sunitinib in Elderly Patients with Advanced Renal Cell Carcinoma at a University Hospital in Japan: Before Immuno-Oncology Therapy Era

In an expanded access trial of sunitinib, median PFS among patients aged over 65 years was 10.1 months compared to 8.9 months for the whole population. Except for fatigue, patients aged over 65 years appear to have experienced no worse grade 3-4 non-hematological adverse events than the whole population of patients.